Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilvegostomig (Primary) ; Capecitabine; Cisplatin; Gemcitabine; Gimeracil/oteracil/tegafur
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms ARTEMIDE-(Biliary01); ARTEMIDE-Bil01
Sponsors AstraZeneca

04 Mar 2026 Status changed from recruiting to active, no longer recruiting.
17 Jul 2025 Planned End Date changed from 30 Sep 2030 to 3 May 2030.
17 Jul 2025 Planned primary completion date changed from 29 Jun 2029 to 2 Jan 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com